Company Filing History:
Years Active: 2022
Title: Yinyu Zhu: Innovator in Transgenic Immune Effector Cells
Introduction
Yinyu Zhu is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of immunotherapy, particularly in the development of transgenic immune effector cells. His innovative work focuses on targeting specific tumor markers to enhance treatment efficacy.
Latest Patents
Yinyu Zhu holds a patent for a groundbreaking invention titled "GPC3 and ASGPR1 double-targeted transgenic immune effector cell and use thereof." This patent describes an immune effector cell capable of identifying gene modifications of GPC3 and ASGPR1 simultaneously. The cell is designed for the treatment of GPC3 and ASGPR1 double-positive tumors, such as liver cancer. This advancement has the potential to improve therapeutic outcomes for patients suffering from these types of cancers.
Career Highlights
Yinyu Zhu is associated with Crage Medical Co., Limited, where he continues to push the boundaries of medical research and innovation. His work is characterized by a commitment to developing effective treatments that leverage the body's immune system to combat cancer.
Collaborations
Yinyu Zhu collaborates with notable colleagues, including Huamao Wang and Xiumei Cai. Their combined expertise contributes to the advancement of research in the field of immunotherapy.
Conclusion
Yinyu Zhu's contributions to the development of transgenic immune effector cells represent a significant advancement in cancer treatment. His innovative approach to targeting specific tumor markers showcases the potential for improved therapeutic strategies in oncology.